Navigation Links
OptiNose presents data on highly effective migraine treatment
Date:6/28/2008

BOSTON, MA Saturday June 28, 2008 OptiNose announced today that it presented important new data demonstrating the superior performance of its novel nasal drug delivery device with sumatriptan for the treatment of migraines. The Phase II results indicate that the drug-device combination achieves migraine relief as quickly and efficiently as injections without the discomfort, inconvenience and risk of needle-stick injuries. OptiNose presented the data at the Annual Scientific Meeting of the American Headache Society in Boston.

Headache relief was achieved in 74.3% and 83.8% of patients at 60 minutes and 120 minutes after administration, respectively, and 48.6% of patients remained pain free after 48 hours. The results were statistically significant when compared to the study's placebo group. The study also confirmed earlier Phase I results. In the Phase I study, the OptiNose powder nasal drug delivery device achieved the maximum sumatriptan concentration in the blood at a median time of 20 minutes after administration. This result was comparable to injections and much faster than other intranasal delivery technologies.

"We are excited to develop this new treatment for the approximately 30 million Americans who suffer from migraines," said Per Djupesland, M.D., Ph.D., the study's co-author and Chief Scientific Officer at OptiNose AS. "Our new device combination will offer patients a much-needed alternative to existing, slower-acting nasal inhalers and tablets and painful injections."

The user feedback from patients who participated in the study was also very encouraging. "The majority of the migraine patients found the device to be both comfortable and easy to use." said Dr Djupesland. "We believe that we can offer a unique therapy for migraine sufferers, combining fast relief, low side effects and high user compliance."

Unlike traditional nasal delivery devices, the unique design of the OptiNose device ensures that drug is delivered to target sites throughout the entire nasal cavity, achieving optimal dose delivery while avoiding the risk of drug deposition to the lungs.


'/>"/>

Contact: Per Djupesland, M.D., Ph.D.
+474-809-0610
OptiNose
Source:Eurekalert

Related medicine news :

1. International Association for Dental Research presents awards and fellowships
2. MIKE AND IKE(R) Lemonade Blends(TM) Presents $100,000 to Alexs Lemonade Stand Foundation
3. Journal STEM CELLS Presents 3rd Annual Young Investigator Award at International Stem Cell Symposium
4. The Montreal Heart Institute presents findings on congestive heart failure and atrial fibrillation
5. Bioniche Presents E. coli O157:H7 Vaccine Data to International Congress of Medical Microbiology in Serbia
6. CEL-SCI Presents Favorable Data for Leaps Vaccine Technology at Prestigious Immunology Conference
7. The febit science lounge presents: Webinar About Role of Non-Protein-Coding RNA in Human Genome Set for 11 a.m. EDT on June 12
8. American College of Rheumatology presents recommendations for rheumatoid arthritis therapy
9. Childrens Health and Fitness To Be Focus of ING Presents Marc Anthony Juntos en Concierto Series
10. Montana Center for Work Physiology and Exercise Metabolism presents firefighter health study
11. Montana Center for Work Physiology and Exercise Metabolism Presents Firefighter Health Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2016)... California (PRWEB) , ... May 28, 2016 , ... "Color ... to drag and drop a preset onto their media," said Christina Austin - CEO ... Film Studios, editors can quickly and easily add stylish color grades to their footage. ...
(Date:5/27/2016)... ... 27, 2016 , ... More than a third of American adults are considered ... surgery has received increased attention in recent years, as an article published ... weight loss, most people are familiar with the basic requirements of maintaining a healthy ...
(Date:5/27/2016)... ... May 27, 2016 , ... An influential resource amongst nurses and ... to shed lights on the variety of topics detailing why we appreciate nurses in ... why this career has gone from being in a major recession to one of ...
(Date:5/27/2016)... ... May 27, 2016 , ... ... help educate the many who are unaware of the plight of aphasia. In ... run within the “Stroke Awareness” campaign. , The link between stroke and aphasia ...
(Date:5/27/2016)... PALMYRA, Wis. (PRWEB) , ... May 27, 2016 ... ... over $90,000 in scholarships to students studying complementary medicine. Allison Outerbridge is this ... She accepted her award on May 18 at the university’s Student Leadership Awards ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... Germany and GERMANTOWN, Maryland , ... QGEN ; Frankfurt Prime Standard: QIA) today announced ... agreement with Therawis Diagnostics GmbH to develop and commercialize predictive ... and market PITX2 as a marker to predict effectiveness of ... patients. "We are pleased to partner with Therawis, ...
(Date:5/25/2016)... 25, 2016 As illustrated by ... this month, the numbers and momentum of cannabis in ... into the billions, more research and development push the ... State of Legal Marijuana Markets Report  from from ArcView ... much of the increase in sector is attributed to ...
(Date:5/25/2016)... CAMBRIDGE, England , May 25, 2016 /PRNewswire/ ... genomics company employing the precision of circulating tumour ... oncology, today announces the appointment of Professor ... will provide medical leadership across the clinical development ... that Inivata,s products help deliver significant improvements in ...
Breaking Medicine Technology: